Oragenics Inc. Common Stock (OGEN)

About OGEN

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

3

Website

www.oragenics.com/

Fundamentals

1-day range

$0.5302$0.5549

Market cap

$2.45M

P/E (trailing)

0.56

P/E (forward)

-0.05

EPS (trailing)

$-5.61

Dividend yield

—

Beta

1.31

Avg. volume

38.5K

Dividend pay date

January 22, 2018

Oragenics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• OGEN

  Oragenics Inc. Common Stock

  $0.5296

  ▼ 0.08%
  Market cap $2.45MP/E 0.56
  $0.4801$1.45
• CDT

  CDT Equity Inc. Common Stock

  $1.69

  ▼ 10.37%
  Market cap $2.54MP/E —
  $1.62$2,928
• ARTL

  Artelo Biosciences Inc. Common Stock

  $0.6619

  ▲ 0.14%
  Market cap $2.62MP/E —
  $0.52$28.14
• SBFM

  Sunshine Biopharma Inc. Common Stock

  $1.16

  ▼ 8.66%
  Market cap $2.97MP/E —
  $1.01$24.3
• MTNB

  Matinas Biopharma Holdings Inc. Common Stock

  $0.1966

  ▼ 1.70%
  Market cap $1.72MP/E —
  $0.178$2.14
• ONCO

  Onconetix Inc. Common Stock

  $0.6121

  ▼ 3.15%
  Market cap $3.34MP/E 0.00
  $0.6207$209.5
• XRTX

  XORTX Therapeutics Inc. Common Shares

  $2.34

  ▼ 4.18%
  Market cap $3.51MP/E —
  $2.42$9.85

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Oragenics Advances Phase IIa Trial With 9 Participants Dosed; Recieved NYSE American Non Compliance Letter, Has 45 Days From Receipt Of The Deficiency Letter Within Which To Submit A Plan To Regain Compliance With The Continued Listing Standards
  benzinga · 8/28/2026

• Spencer John · July 1, 2026 · Grant

  55.9K

Institutional Ownership

March 31, 2026

Total shares held

190.4K

Total value held

$86.4K

Institutional holders

21